Trials / Completed
CompletedNCT06108297
Lithium Long COVID Dose-finding Study
Effect of Low-dose Lithium Therapy on Long COVID Symptoms: an Open-label, Dose-finding Study.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- State University of New York at Buffalo · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This open-label study will assess if lithium dosages of 30-45mg/day are associated with greater symptomatic benefit than dosages of 10-15mg/day previously assessed among 50 patients with long COVID.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Lithium | Elemental lithium as lithium aspartate. |
Timeline
- Start date
- 2023-10-12
- Primary completion
- 2024-03-26
- Completion
- 2024-05-02
- First posted
- 2023-10-31
- Last updated
- 2024-10-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06108297. Inclusion in this directory is not an endorsement.